|
FI3056514T4
(fi)
|
2008-01-15 |
2025-10-06 |
Univ Leland Stanford Junior |
Menetelmät cd47:n välittämän fagosytoosin manipuloimiseksi
|
|
US9221908B2
(en)
|
2012-12-12 |
2015-12-29 |
Vasculox, Inc. |
Therapeutic CD47 antibodies
|
|
HK1216647A1
(zh)
|
2012-12-12 |
2016-11-25 |
Vasculox Inc. |
治疗性cd47抗体
|
|
US9969789B2
(en)
|
2012-12-17 |
2018-05-15 |
Trillium Therapeutics Inc. |
Treatment of CD47+ disease cells with SIRP alpha-Fc fusions
|
|
WO2016015095A1
(en)
*
|
2014-07-31 |
2016-02-04 |
The University Of Western Australia |
A method for the identification of immunotherapy-drug combinations using a network approach
|
|
AU2015329696A1
(en)
*
|
2014-10-10 |
2017-04-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods to eliminate cancer stem cells by targeting CD47
|
|
CA2967379A1
(en)
*
|
2014-11-18 |
2016-05-26 |
Janssen Pharmaceutica Nv |
Cd47 antibodies, methods, and uses
|
|
KR102617691B1
(ko)
|
2014-12-05 |
2023-12-27 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화 분화 클러스터 47 유전자를 가진 비인간 동물
|
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
|
WO2016141328A2
(en)
*
|
2015-03-04 |
2016-09-09 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind cd47
|
|
CN104804093A
(zh)
*
|
2015-05-27 |
2015-07-29 |
江苏春申堂药业有限公司 |
一种针对cd47的单域抗体
|
|
PL3341015T5
(pl)
|
2015-08-26 |
2024-04-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Zwiększona deplecja komórek docelowych z blokadą cd47 i immunologicznym agonistą kostymulatorowym
|
|
CA2998548A1
(en)
*
|
2015-09-10 |
2017-03-16 |
Affigen, Inc. |
Sequencing-directed selection of tumor theranostics
|
|
EP3349787A4
(en)
|
2015-09-18 |
2019-03-27 |
Arch Oncology, Inc. |
THERAPEUTIC CD47 ANTIBODIES
|
|
AU2016326423A1
(en)
|
2015-09-21 |
2018-04-26 |
Erasmus University Medical Center |
Anti-CD47 antibodies and methods of use
|
|
CN116121281B
(zh)
|
2015-11-27 |
2026-01-02 |
卡瑟里克斯私人有限公司 |
经遗传修饰的细胞及其用途
|
|
US11253590B2
(en)
|
2015-12-02 |
2022-02-22 |
Stsciences, Inc. |
Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
|
|
KR20220163516A
(ko)
|
2016-01-11 |
2022-12-09 |
포티 세븐, 인코포레이티드 |
인간화된, 마우스 또는 키메라 항-cd47 단클론 항체
|
|
EP3405499A4
(en)
*
|
2016-01-21 |
2020-03-18 |
The Board of Trustees of the Leland Stanford Junior University |
TREATMENT OF CANCER WITH COMBINATIONS OF IMMUNOREGULATORS
|
|
US20190091290A1
(en)
*
|
2016-04-15 |
2019-03-28 |
Trillium Therapeutics Inc. |
Macrophage stimulation in cd47 blockade therapy
|
|
CN106084052B
(zh)
|
2016-06-17 |
2019-12-27 |
长春金赛药业股份有限公司 |
抗cd47单克隆抗体及其应用
|
|
US12344669B2
(en)
|
2016-06-17 |
2025-07-01 |
Changchun Genescience Pharmaceutical Co., Ltd. |
Anti-CD47 monoclonal antibody and use thereof
|
|
CN106117354B
(zh)
*
|
2016-06-24 |
2020-01-14 |
安徽未名细胞治疗有限公司 |
一种全人源抗CD47的全分子IgG抗体及其应用
|
|
JP7241677B2
(ja)
|
2016-07-19 |
2023-03-17 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
抗ｃｄ４７併用療法
|
|
CA2999058C
(en)
|
2016-10-20 |
2024-03-12 |
I-Mab |
Novel cd47 monoclonal antibodies and uses thereof
|
|
WO2018075960A1
(en)
|
2016-10-21 |
2018-04-26 |
Tioma Therapeutics, Inc. |
Therapeutic cd47 antibodies
|
|
CA3042581A1
(en)
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Enhancement of cd47 blockade therapy by proteasome inhibitors
|
|
WO2018095428A1
(zh)
*
|
2016-11-28 |
2018-05-31 |
江苏恒瑞医药股份有限公司 |
Cd47抗体、其抗原结合片段及其医药用途
|
|
EP3345924A1
(en)
*
|
2017-01-10 |
2018-07-11 |
Universität Duisburg-Essen |
Use of cd47 antibodies
|
|
GB201700621D0
(en)
|
2017-01-13 |
2017-03-01 |
Guest Ryan Dominic |
Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
|
|
WO2018137705A1
(en)
*
|
2017-01-26 |
2018-08-02 |
Zai Lab (Shanghai) Co., Ltd. |
Cd47 antigen binding unit and uses thereof
|
|
MX2019011624A
(es)
*
|
2017-03-27 |
2019-12-05 |
Celgene Corp |
Metodos y composiciones para la reduccion de la inmunogenicidad.
|
|
CA3057718A1
(en)
*
|
2017-03-28 |
2018-10-04 |
Trillium Therapeutics Inc. |
Cd47 blockade therapy
|
|
CA3069523A1
(en)
|
2017-07-11 |
2019-01-17 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
JP7262440B2
(ja)
*
|
2017-08-02 |
2023-04-21 |
フェインズ セラピューティクス，インコーポレーテッド |
抗ｃｄ４７抗体及びその使用
|
|
JP7256580B2
(ja)
|
2017-08-18 |
2023-04-12 |
ウルトラヒューマン フォー リミティド |
結合剤
|
|
CN109422811A
(zh)
|
2017-08-29 |
2019-03-05 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
|
RU2698048C2
(ru)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
|
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
|
US11802153B2
(en)
*
|
2017-10-18 |
2023-10-31 |
Forty Seven, Inc. |
Anti-CD47 agent-based ovarian cancer therapy
|
|
KR20200079511A
(ko)
|
2017-11-01 |
2020-07-03 |
허밍버드 바이오사이언스 홀딩스 피티이. 엘티디. |
Cd47 항원-결합 분자
|
|
WO2019090355A1
(en)
*
|
2017-11-06 |
2019-05-09 |
Children's National Medical Center |
Cells expressing antibodies and methods of treatment using the same
|
|
CA3080640C
(en)
|
2017-11-06 |
2024-04-09 |
Trillium Therapeutics Inc. |
Cd47 blockade with radiation therapy
|
|
KR20200091901A
(ko)
|
2017-12-01 |
2020-07-31 |
시애틀 지네틱스, 인크. |
암을 치료하기 위한 cd47 항체 및 이의 용도
|
|
CN110144009B
(zh)
*
|
2018-02-14 |
2020-01-21 |
上海洛启生物医药技术有限公司 |
Cd47单域抗体及其用途
|
|
CN110305212A
(zh)
|
2018-03-27 |
2019-10-08 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
|
GB201804860D0
(en)
|
2018-03-27 |
2018-05-09 |
Ultrahuman Two Ltd |
CD47 Binding agents
|
|
WO2019200462A1
(en)
*
|
2018-04-16 |
2019-10-24 |
Adaerata, Limited Partnership |
Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers
|
|
CN108484770B
(zh)
*
|
2018-05-16 |
2020-11-13 |
武汉云克隆科技股份有限公司 |
重组大鼠抗小鼠cd4单克隆抗体，制备方法和应用
|
|
CN110538321B
(zh)
*
|
2018-05-29 |
2023-03-10 |
江苏恒瑞医药股份有限公司 |
一种cd47抗体药物组合物及其用途
|
|
US11634490B2
(en)
|
2018-06-15 |
2023-04-25 |
Accurus Biosciences, Inc. |
Blocking antibodies against CD47 and methods of use thereof
|
|
CN110615841B
(zh)
*
|
2018-06-20 |
2022-01-04 |
瑞阳(苏州)生物科技有限公司 |
抗人cd47单克隆抗体及其应用
|
|
EP3820992A2
(en)
|
2018-07-11 |
2021-05-19 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
CN112805029A
(zh)
*
|
2018-08-13 |
2021-05-14 |
安驰肿瘤公司 |
治疗性cd47抗体
|
|
EP3844276A2
(en)
|
2018-08-28 |
2021-07-07 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
CN110872350B
(zh)
*
|
2018-08-31 |
2023-04-07 |
南京圣和药业股份有限公司 |
抗cd47抗体及其应用
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
AU2019370031A1
(en)
*
|
2018-10-29 |
2021-05-27 |
Umc Utrecht Holding B.V. |
IgA mediated killing of aberrant cells by CD47- SIRPα checkpoint inhibition of neutrophils
|
|
EP3876977A1
(en)
|
2018-11-06 |
2021-09-15 |
The Regents Of The University Of California |
Chimeric antigen receptors for phagocytosis
|
|
CN111253488A
(zh)
*
|
2018-12-03 |
2020-06-09 |
上海开拓者生物医药有限公司 |
Cd47抗体及其制备方法和应用
|
|
US20230012428A1
(en)
|
2019-03-06 |
2023-01-12 |
Jiangsu Hengrui Medicine Co., Ltd. |
Bifunctional fusion protein and pharmaceutical use thereof
|
|
US11013764B2
(en)
|
2019-04-30 |
2021-05-25 |
Myeloid Therapeutics, Inc. |
Engineered phagocytic receptor compositions and methods of use thereof
|
|
MA56119A
(fr)
|
2019-06-07 |
2022-04-13 |
Alx Oncology Inc |
Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques
|
|
EP3986935A4
(en)
|
2019-06-19 |
2023-08-30 |
Lepu Biopharma Co., Ltd. |
Anti-cd47 antibodies and uses thereof
|
|
WO2020253785A1
(en)
*
|
2019-06-19 |
2020-12-24 |
Lepu Biopharma Co., Ltd. |
Anti-cd47 antibodies and uses thereof
|
|
CA3145791A1
(en)
|
2019-07-16 |
2021-01-21 |
Gilead Sciences, Inc. |
Hiv vaccines and methods of making and using
|
|
MX2022001305A
(es)
*
|
2019-07-30 |
2022-05-06 |
Akeso Biopharma Inc |
Anticuerpo de dominio proteínico p40 anti-humana y uso del mismo.
|
|
CN114981409A
(zh)
|
2019-09-03 |
2022-08-30 |
美洛德生物医药公司 |
用于基因组整合的方法和组合物
|
|
PH12022550489A1
(en)
*
|
2019-09-03 |
2022-12-12 |
Akeso Biopharma Inc |
Anti-cd47 monoclonal antibody and use thereof
|
|
MX2022004370A
(es)
|
2019-10-18 |
2022-05-06 |
Forty Seven Inc |
Terapias de combinacion para tratar sindromes mielodisplasicos y leucemia mieloide aguda.
|
|
AU2020372522B2
(en)
|
2019-10-25 |
2024-08-15 |
WuXi Biologics Ireland Limited |
Novel anti-CD47 antibodies and uses thereof
|
|
WO2021087064A1
(en)
|
2019-10-31 |
2021-05-06 |
Forty Seven, Inc. |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
EP4061420A1
(en)
*
|
2019-11-20 |
2022-09-28 |
Abvision, Inc. |
Monoclonal antibodies that target human cd47 protein
|
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
|
GB201918230D0
(en)
|
2019-12-11 |
2020-01-22 |
Prec Therapeutics Ltd |
Antibodies and their uses
|
|
CN115244173A
(zh)
|
2019-12-20 |
2022-10-25 |
英研生物(英国)有限公司 |
用于分离肿瘤浸润淋巴细胞的装置及方法及其用途
|
|
JP7711068B2
(ja)
|
2019-12-24 |
2025-07-22 |
カルナバイオサイエンス株式会社 |
ジアシルグリセロールキナーゼ調節化合物
|
|
IL295023A
(en)
|
2020-02-14 |
2022-09-01 |
Jounce Therapeutics Inc |
Antibodies and fusion proteins that bind to ccr8 and their uses
|
|
WO2021190441A1
(zh)
*
|
2020-03-23 |
2021-09-30 |
倍而达药业（苏州）有限公司 |
Cd47/人源化cd47抗体或其抗原结合片段、免疫活性片段及应用
|
|
WO2021191870A1
(en)
|
2020-03-27 |
2021-09-30 |
Dcprime B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
CN115190887B
(zh)
*
|
2020-04-02 |
2025-05-02 |
正大天晴药业集团股份有限公司 |
结合cd47的抗原结合多肽及用途
|
|
CN111635459B
(zh)
*
|
2020-06-27 |
2021-01-15 |
广东赛尔生物科技有限公司 |
抗cd47抗体及其在治疗癌症中的应用
|
|
JP2023531537A
(ja)
|
2020-06-30 |
2023-07-24 |
メンドゥス・ベスローテン・フェンノートシャップ |
卵巣癌ワクチンでの白血病由来細胞の使用
|
|
WO2022098642A1
(en)
|
2020-11-03 |
2022-05-12 |
Rdiscovery, LLC |
Therapies for treatment of cancer and phagocytosis-deficiency related diseases
|
|
EP4240367A4
(en)
|
2020-11-04 |
2024-10-16 |
Myeloid Therapeutics, Inc. |
MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
|
|
CN116600826A
(zh)
*
|
2020-11-04 |
2023-08-15 |
达特茅斯学院理事会 |
用于治疗/预防缺血性和/或再灌注损伤的vista激动剂
|
|
EP4256336A1
(en)
|
2020-12-06 |
2023-10-11 |
ALX Oncology Inc. |
Multimers for reducing the interference of drugs that bind cd47 in serological assays
|
|
EP4262828A1
(en)
|
2020-12-18 |
2023-10-25 |
Instil Bio (Uk) Limited |
Tumor infiltrating lymphocytes and anti-cd47 therapeutics
|
|
MX2023009717A
(es)
*
|
2021-02-19 |
2024-01-08 |
Shaperon Inc |
Anticuerpo de dominio individual contra cúmulo de diferenciación 47 (cd47) y uso del mismo.
|
|
CA3212351A1
(en)
|
2021-03-12 |
2022-09-15 |
Mendus B.V. |
Methods of vaccination and use of cd47 blockade
|
|
CN112979764B
(zh)
*
|
2021-03-26 |
2022-08-02 |
复旦大学附属中山医院 |
特异结合人cd47分子的多肽及其用途
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
CA3218780A1
(en)
|
2021-05-11 |
2022-11-17 |
Daniel Getts |
Methods and compositions for genomic integration
|
|
AU2022299051B2
(en)
|
2021-06-23 |
2025-03-13 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
KR20240025616A
(ko)
|
2021-06-23 |
2024-02-27 |
길리애드 사이언시즈, 인코포레이티드 |
다이아실글리세롤 키나제 조절 화합물
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
AU2022298639C1
(en)
|
2021-06-23 |
2025-07-17 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
JP2024539252A
(ja)
|
2021-10-28 |
2024-10-28 |
ギリアード サイエンシーズ， インコーポレイテッド |
ピリジジン－３（２ｈ）－オン誘導体
|
|
CA3235986A1
(en)
|
2021-10-29 |
2023-05-04 |
Gilead Science, Inc. |
Cd73 compounds
|
|
EP4667056A1
(en)
|
2021-12-22 |
2025-12-24 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
EP4452414A2
(en)
|
2021-12-22 |
2024-10-30 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
WO2023159220A1
(en)
*
|
2022-02-18 |
2023-08-24 |
Kenjockety Biotechnology, Inc. |
Anti-cd47 antibodies
|
|
LT4245756T
(lt)
|
2022-03-17 |
2024-11-25 |
Gilead Sciences, Inc. |
Ikaros cinko pirštų šeimos skaidymo medžiagos ir jų panaudojimas
|
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
US20230374036A1
(en)
|
2022-04-21 |
2023-11-23 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
IL317958A
(en)
|
2022-07-01 |
2025-02-01 |
Gilead Sciences Inc |
CD73 compounds
|
|
JP2025523043A
(ja)
|
2022-07-12 |
2025-07-17 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖ免疫原性ポリペプチド及びワクチン、並びにその使用
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
EP4695260A1
(en)
|
2023-04-11 |
2026-02-18 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
KR20250175331A
(ko)
|
2023-04-21 |
2025-12-16 |
길리애드 사이언시즈, 인코포레이티드 |
Prmt5 억제제 및 이의 용도
|
|
AU2024306338A1
(en)
|
2023-06-30 |
2026-01-08 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
AU2024300557A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025054530A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
CN120648654A
(zh)
*
|
2024-03-13 |
2025-09-16 |
深圳太力生物技术有限责任公司 |
重组细胞的制备方法、重组细胞及其应用
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026039365A1
(en)
|
2024-08-12 |
2026-02-19 |
Gilead Sciences, Inc. |
Kras modulating compounds
|